Social determinants of health (SDH) can influence some outcomes related to multiple sclerosis (MS), including disability accrual and disease progression. The relationship between SDH and MS is complex, due to interplay between factors and bidirectionality. Inequities also occur in countries with universal health care system like Italy.
Objectives:
To identify and synthesize the existing and emerging literature on several SDH in the Italian population with MS: sex, gender and sexuality; race, ethnicity and geographical area; education; employment; socioeconomic status; domestic abuse; healthcare access; food access, diet, and obesity; pollution; social support.
Methods:
Eleven PubMed search strings identified studies published in the past decade and material from ECTRIMS 2024 congress was examined.
Results:
In total, 214 studies were included, contributing to 284 SDH findings. More than one-third of the papers focused on sex and gender while just one on domestic abuse; many articles presented results on several SDH simultaneously, especially for education and employment (N = 14) and healthcare access and social support (N = 10). Bidirectional associations between SDH and MS were documented and several unmet needs and disparities were shown.
Conclusion:
Disproportionality in thematic areas of research was observed and some gaps were identified; the importance of accounting for SDH in the healthcare context emerged.
DobsonRRiceDRD’hoogheM, et al. Social determinants of health in multiple sclerosis. Nat Rev Neurol2022; 18(12): 723–734.
3.
Van Den BergMFlavelJSchramA, et al. Social, cultural and political conditions for advancing health equity: Examples from eight country case studies (2011–2021). BMJ Glob Health2024; 9(Suppl. 1): e015694.
4.
MunezeroEManoukianS. The social determinants of health and health seeking behaviour in populations affected by armed conflict: A qualitative systematic review. Med Confl Surviv2021; 37(4): 293–318.
5.
ShahGHShankarPSchwindJS, et al. The detrimental impact of the COVID-19 crisis on health equity and social determinants of health. J Public Health Manag Pract2020; 26(4): 317–319.
6.
LefortMDejardinOBergerE, et al. Association between education level and disability progression in patients with multiple sclerosis in France. Mult Scler2024; 31: 59–68.
7.
KavaliunasADanylaitė KarrenbauerVBinzerS, et al. Systematic review of the socioeconomic consequences in patients with multiple sclerosis with different levels of disability and cognitive function. Front Neurol2022; 12: 737211.
8.
CooksonRAsariaMAliS, et al. Health equity indicators for the English NHS: A longitudinal whole-population study at the small-area level. Health Serv Deliv Res2016; 4(26): 1–224.
9.
MatrangaDManiscalcoL. Inequality in healthcare utilization in Italy: How important are barriers to access?IJERPH2022; 19(3): 1697.
10.
FranziniLGiannoniM. Determinants of health disparities between Italian regions. BMC Public Health2010; 10(1): 296.
11.
PatacchiniE. Local analysis of economic disparities in Italy: A spatial statistics approach. Stat Meth & Appl2008; 17(1): 85–112.
12.
BruzziSIvaldiESantagataM. Measuring regional performance in the Italian NHS: Are disparities decreasing?Soc Indic Res2022; 159(3): 1057–1084.
TaneseA. A new challenge for Italy’s National Healthcare System. Hosp Admin Med Pract2023; 2. Available at: https://www.hksmp.com/hamp/article/view/728 (accessed 25 August 2025).
15.
PonzioMPoddaJPignattelliE, et al. Work difficulties in people with multiple sclerosis. J Occup Rehabil2024; 34(3): 606–617.
16.
PonzioMBrichettoGZaratinP, et al. Workers with disability: The case of multiple sclerosis. Neurol Sci2015; 36(10): 1835–1841.
17.
PonzioMTacchinoAVaccaroC, et al. Disparity between perceived needs and service provision: A cross-sectional study of Italians with multiple sclerosis. Neurol Sci2019; 40(6): 1137–1144.
18.
BorreaniCBianchiEPietrolongoE, et al. Unmet needs of people with severe multiple sclerosis and their carers: Qualitative findings for a home-based intervention. PLoS ONE2014; 9(10): e109679.
19.
BergamaschiRBeghiEBosettiC, et al. Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. Neurol Sci2022; 43(9): 5459–5469.
20.
BattagliaMABezziniDCecchiniI, et al. Patients with multiple sclerosis: A burden and cost of illness study. J Neurol2022; 269(9): 5127–5135.
21.
RosatoRPaganoEGiordanoA, et al. Living with severe multiple sclerosis: Cost-effectiveness of a palliative care intervention and cost of illness study. Mult Scler Relat Disord2021; 49: 102756.
22.
PonzioMGerzeliSBrichettoG, et al. Economic impact of multiple sclerosis in Italy: Focus on rehabilitation costs. Neurol Sci2015; 36(2): 227–234.
23.
KaufmanMREschlimanELKarverTS. Differentiating sex and gender in health research to achieve gender equity. Bull World Health Organ2023; 101(10): 666–671.
24.
MianiCWandschneiderLNiemannJ, et al. Measurement of gender as a social determinant of health in epidemiology—A scoping review. PLoS ONE2021; 16(11): e0259223.
PetersMDJGodfreyCMKhalilH, et al. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc2015; 13(3): 141–146.
27.
TriccoACLillieEZarinW, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med2018; 169(7): 467–473.
28.
GuerraTPipoliAViterboRG, et al. Predictors of unemployment status in people with relapsing multiple sclerosis: A single center experience. Neurol Sci2022; 43(7): 4387–4392.
29.
LoreficeLFenuGFrauJ, et al. The impact of visible and invisible symptoms on employment status, work and social functioning in multiple sclerosis. WOR2018; 60(2): 263–270.
30.
LavorgnaLMocciaMRussoA, et al. Health-care disparities stemming from sexual orientation of Italian patients with multiple sclerosis: A cross-sectional web-based study. Mult Scler Relat Disord2017; 13: 28–32.
31.
GiossiRMercenariMFilippiM, et al. Unprescribed cannabinoids and multiple sclerosis: A multicenter, cross-sectional, epidemiological study in Lombardy, Italy. J Neurol2024; 271(11): 7186–7205.
32.
GroppoESignoriASormaniMP, et al. Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: A large-scale, single-centre study. Mult Scler J Exp Transl Clin2019; 5(2): 2055217319843673.
33.
D’AmicoEPattiFZanghìA, et al. Late-onset and young-onset relapsing-remitting multiple sclerosis: Evidence from a retrospective long-term follow-up study. Eur J Neurol2018; 25(12): 1425–1431.
34.
PauMCoronaFPilloniG, et al. Do gait patterns differ in men and women with multiple sclerosis?Mult Scler Relat Disord2017; 18: 202–208.
35.
MistriDCacciaguerraLStorelliL, et al. The association between cognition and motor performance is beyond structural damage in relapsing–remitting multiple sclerosis. J Neurol2022; 269(8): 4213–4221.
36.
BonacchiRValsasinaPPaganiE, et al. Sex-related differences in upper limb motor function in healthy subjects and multiple sclerosis patients: A multiparametric MRI study. J Neurol2023; 270(11): 5235–5250.
37.
PauMCasuGPortaM, et al. Timed up and go in men and women with multiple sclerosis: Effect of muscular strength. J Bodyw Mov Ther2020; 24(4): 124–130.
38.
SolaroCTrabuccoESignoriA, et al. Italian validation of the 12-item multiple sclerosis walking scale. Mult Scler Int2015; 2015: 540828.
39.
TacchinoABrichettoGZaratinP, et al. Self-assessment reliability in multiple sclerosis: The role of socio-demographic, clinical, and quality of life aspects. Neurol Sci2019; 40(3): 617–620.
40.
TedoneNPreziosaPMeaniA, et al. Regional white matter and gray matter damage and cognitive performances in multiple sclerosis according to sex. Mol Psychiatry2023; 28(4): 1783–1792.
41.
ReiaAPetruzzoMFalcoF, et al. A retrospective exploratory analysis on cardiovascular risk and cognitive dysfunction in multiple sclerosis. Brain Sciences2021; 11(4): 502.
42.
GajofattoATurattiMBianchiMR, et al. Benign multiple sclerosis: Physical and cognitive impairment follow distinct evolutions. Acta Neurol Scand2016; 133(3): 183–191.
43.
PoddaJPonzioMPedullàL, et al. Predominant cognitive phenotypes in multiple sclerosis: Insights from patient-centered outcomes. Mult Scler Relat Disord2021; 51: 102919.
44.
MenculiniGGentiliLGaetaniL, et al. Clinical correlates of state and trait anxiety in multiple sclerosis. Mult Scler Relat Disord2023; 69: 104431.
45.
CapuanoRAltieriMBiseccoA, et al. Psychological consequences of COVID-19 pandemic in Italian MS patients: Signs of resilience?J Neurol2021; 268(3): 743–750.
46.
MistriDMargoniMPaganiE, et al. Structural and functional imaging features of cognitive phenotypes in pediatric multiple sclerosis. Ann Clin Transl Neurol2024; 11(7): 1840–1851.
47.
LanzilloRChiodiACarotenutoA, et al. Quality of life and cognitive functions in early onset multiple sclerosis. Eur J Paediatr Neurol2016; 20(1): 158–163.
48.
BezziniDGualdaniERazzanelliM, et al. Prevalence of chronic comorbidities in people with multiple sclerosis: Descriptive study based on administrative data in Tuscany (Central Italy). Neurol Sci2022; 43(11): 6407–6414.
49.
PompaAClemenziATroisiE, et al. Chronic pain in multiple sclerosis patients: Utility of sensory quantitative testing in patients with fibromyalgia comorbidity. Eur Neurol2015; 73(5–6): 257–263.
50.
AlvinoBAriannaFAssuntaB, et al. Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: An Italian multicenter study. J Neurol2022; 269(3): 1610–1617.
51.
Monti BragadinMMottaRMessmer UccelliM, et al. Lower urinary tract dysfunction in patients with multiple sclerosis: A post-void residual analysis of 501 cases. Mult Scler Relat Disord2020; 45: 102378.
52.
CarotenutoADe GiglioLChiodiA, et al. Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19. Neurol Sci2021; 42(7): 2903–2910.
53.
Anon. ECTRIMS 2024–poster. Mult Scler2024; 30(Suppl. 3): 125–680.
54.
TrombaLBlasiSVestriA, et al. Prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: A blinded sonographic evaluation. Phlebology2015; 30(1): 52–60.
55.
KoudriavtsevaTPlantoneDRennaR, et al. Interferon-β therapy and risk of thrombocytopenia in multiple sclerosis patients. Neurol Sci2015; 36(12): 2263–2268.
56.
SellittoGRuotoloIIannielloA, et al. Clinical variables influencing the perception of fatigue in people with multiple sclerosis: A cross-sectional study using FSIQ-RMS. BMC Neurol2024; 24(1): 138.
57.
OttonelloMPellicciariLGiordanoA, et al. Rasch analysis of the Fatigue Severity Scale in Italian subjects with multiple sclerosis. J Rehabil Med2016; 48(7): 597–603.
58.
FerrèLMogaveroAClarelliF, et al. Early evidence of disease activity during Fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis. Mult Scler2021; 27(9): 1374–1383.
59.
SottiniAQuaresimaVBarbaroM, et al. Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab. J Neuroimmunol2023; 382: 578170.
60.
ManniADirenzoVIaffaldanoA, et al. Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort. Brain Behav2017; 7(10): e00804.
61.
DinotoASartoriACheliM, et al. Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence, predicting factors and clinical outcomes. Mult Scler Relat Disord2022; 57: 103357.
62.
GarboRLorenzutSDel NegroI, et al. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment. Mult Scler Relat Disord2021; 49: 102781.
63.
MocciaMSantoniLVaccariI, et al. Utilization of peginterferon-β-1a in the real-world practice for relapsing-remitting multiple sclerosis. Eur Rev Med Pharmacol Sci2024; 28(1): 411–418.
64.
D’AmicoEZanghìASciandraM, et al. Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: A 24-month real-world experience. J Neurol2019; 266(2): 411–416.
65.
MocciaMPalladinoRCarotenutoA, et al. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis. Mult Scler Relat Disord2016; 10: 90–96.
66.
R.I.Re.MS study group; LanzilloRProsperiniL, et al. A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: The RESPECT study. J Neurol2018; 265(5): 1174–1183.
67.
MarangiAFarinaGVicenziV, et al. Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy. Mult Scler Relat Disord2020; 41: 102004.
68.
LugaresiADe RobertisFClericoM, et al. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: The RIVER study. Expert Opin Drug Deliv2016; 13(7): 931–935.
69.
NicolellaVFiorenzaMMonteiroI, et al. Clinical utility of the LumipulseTM immunoassay for plasma neurofilament light chain in multiple sclerosis. J Neurol Sci2024; 463: 123115.
70.
SignorielloEMallardoMNigroE, et al. Adiponectin in cerebrospinal fluid from patients affected by multiple sclerosis is correlated with the progression and severity of disease. Mol Neurobiol2021; 58(6): 2663–2670.
71.
AnnesiFHermoso-DuránSRizzutiB, et al. Thermal Liquid Biopsy (TLB) of blood plasma as a potential tool to help in the early diagnosis of multiple sclerosis. JPM2021; 11(4): 295.
72.
GMD-CGFM, et al. Platelet glutamate uptake and Th1 cells inversely correlate in relapsing/remitting and in progressive multiple sclerosis. Mult Scler Relat Disord2020; 41: 102007.
73.
VeroniCMarnettoFGranieriL, et al. Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis. J Neuroinflammation2015; 12(1): 132.
74.
ManiscalcoGTScavoneCMascoloA, et al. The safety profile of COVID-19 vaccines in patients diagnosed with multiple sclerosis: A retrospective observational study. JCM2022; 11(22): 6855.
75.
ImmovilliPSchiavettiICordioliC, et al. Lung involvement correlates with disability in MS patients with COVID-19 pneumonia. Neurol Sci2022; 43(12): 6657–6659.
76.
CapassoNPalladinoRMontellaE, et al. Prevalence of SARS-CoV-2 antibodies in multiple sclerosis: The hidden part of the iceberg. JCM2020; 9(12): 4066.
77.
Torri ClericiVBrambillaLPolitiPL, et al. Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study. Mult Scler Relat Disord2023; 74: 104711.
78.
PauMPortaMCogheG, et al. Does multiple sclerosis differently impact physical activity in women and man? A quantitative study based on Wearable accelerometers. IJERPH2020; 17(23): 8848.
79.
BianchiAMatrangaDPattiF, et al. The role of ethnicity and native-country income in multiple sclerosis: The Italian multicentre study (MS-MigIT). J Neurol2024; 271(5): 2182–2194.
80.
NiglioTMandolesiSDe LuciaO, et al. The incidence of the multiple sclerosis in Italy: 2011-2015. Clin Ter2022; 173(5): 453–457.
81.
AffinitoGPalladinoRCarotenutoA, et al. Epidemiology of multiple sclerosis in the Campania Region (Italy): Derivation and validation of an algorithm to calculate the 2015-2020 incidence. Mult Scler Relat Disord2023; 71: 104585.
82.
GnaviRPicarielloRAlboiniPE, et al. Validation of an algorithm to detect multiple sclerosis cases in administrative health databases in Piedmont (Italy): An application to the estimate of prevalence by age and urbanization level. Neuroepidemiology2021; 55(2): 119–125.
83.
BergamaschiRMontiMCTrivelliL, et al. Increased prevalence of multiple sclerosis and clusters of different disease risk in Northern Italy. Neurol Sci2020; 41(5): 1089–1095.
84.
BezziniDPepePProfiliF, et al. Multiple sclerosis spatial cluster in Tuscany. Neurol Sci2017; 38(12): 2183–2187.
85.
BargagliAMColaisPAgabitiN, et al. Prevalence of multiple sclerosis in the Lazio region, Italy: Use of an algorithm based on health information systems. J Neurol2016; 263(4): 751–759.
86.
MontiMCGuidoDMontomoliC, et al. Is Geo-environmental exposure a risk factor for multiple sclerosis? A population-based cross-sectional study in South-Western Sardinia. PLoS ONE2016; 11(9): e0163313.
87.
BezziniDKundisovaLGoriF, et al. Mortality trend for multiple sclerosis in Italy during the period 1980–2015. Mult Scler Relat Disord2020; 44: 102240.
88.
LeporeVPalettaPBosettiC, et al. Temporal and spatial patterns in the prescriptions of disease-modifying therapies for multiple sclerosis. Results from the Italian Multiple Sclerosis and Related Disorders Register. Mult Scler Relat Disord2024; 87: 105638.
89.
SharminSRoosISimpson-YapS, et al. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Brain2023; 146(11): 4633–4644.
90.
SolariAGiovannettiAMGiordanoA, et al. Conversion to secondary progressive multiple sclerosis: Patient awareness and needs. Results from an online survey in Italy and Germany. Front Neurol2019; 10: 916.
91.
Warrender-SparkesMSpelmanTIzquierdoG, et al. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Mult Scler2016; 22(4): 520–532.
92.
PonzanoMSchiavettiIBovisF, et al. A multiparametric score for assessing the individual risk of severe COVID-19 among patients with multiple sclerosis. Mult Scler Relat Disord2022; 63: 103909.
93.
LoraschiABellantonioPBortolonF, et al. Use of herbal remedies by multiple sclerosis patients: A nation-wide survey in Italy. Neurol Sci2016; 37(4): 613–622.
94.
PESMPE, et al. Cognitive reserve is a determinant of social and occupational attainment in patients with pediatric and adult onset multiple sclerosis. Mult Scler Relat Disord2020; 42: 102145.
95.
RaggiAGiovannettiAMSchiavolinS, et al. Older age, higher perceived disability and depressive symptoms predict the amount and severity of work-related difficulties in persons with multiple sclerosis. Disabil Rehabil2019; 41(19): 2255–2263.
96.
PonzioMTacchinoAZaratinP, et al. Unmet care needs of people with a neurological chronic disease: A cross-sectional study in Italy on multiple sclerosis. Eur J Public Health2015; 25(5): 775–780.
97.
MaidaEAbbadessaGCoccoE, et al. Identifying definite patterns of unmet needs in patients with multiple sclerosis using unsupervised machine learning. Neurol Sci2024; 45(7): 3333–3345.
98.
PattiFChisariCGArenaS, et al. Factors driving delayed time to multiple sclerosis diagnosis: Results from a population-based study. Mult Scler Relat Disord2022; 57: 103361.
99.
VirgilioEVecchioDSarnelliMF, et al. Early predictors of disability and cognition in multiple sclerosis patients: A long-term retrospective analysis. JCM2023; 12(2): 685.
100.
AltieriMFratinoMMaestriniI, et al. Cognitive performance in relapsing-remitting multiple sclerosis: At risk or impaired?Dement Geriatr Cogn Disord2020; 49(6): 539–543.
101.
RaimoSTrojanoLGaitaM, et al. Relationship between apathy and cognitive dysfunctions in multiple sclerosis: A 4-year prospective longitudinal study. Mult Scler Relat Disord2022; 63: 103929.
102.
AmatoMPGorettiBGhezziA, et al. Neuropsychological features in childhood and juvenile multiple sclerosis: Five-year follow-up. Neurology2014; 83(16): 1432–1438.
103.
Della CorteMSantangeloGBiseccoA, et al. A simple measure of cognitive reserve is relevant for cognitive performance in MS patients. Neurol Sci2018; 39(7): 1267–1273.
104.
NunnariDDe ColaMCCostaA, et al. Exploring cognitive reserve in multiple sclerosis: New findings from a cross-sectional study. J Clin Exp Neuropsychol2016; 38(10): 1158–1167.
105.
MaggiGAltieriMRisiM, et al. Vocabulary knowledge as a reliable proxy of cognitive reserve in multiple sclerosis: A validation study. Neurol Sci2024; 45(8): 3931–3938.
106.
MarchesiOVizzinoCMeaniA, et al. Fatigue in multiple sclerosis patients with different clinical phenotypes: A clinical and magnetic resonance imaging study. Eur J Neurol2020; 27(12): 2549–2560.
107.
SumowskiJFRoccaMALeavittVM, et al. Reading, writing, and reserve: Literacy activities are linked to hippocampal volume and memory in multiple sclerosis. Mult Scler2016; 22(12): 1621–1625.
108.
PoddaJPonzioMMessmer UccelliM, et al. Predictors of clinically significant anxiety in people with multiple sclerosis: A one-year follow-up study. Mult Scler Relat Disord2020; 45: 102417.
109.
BujaAGraffignaGMafriciSF, et al. Adherence to therapy, physical and mental quality of life in patients with multiple sclerosis. JPM2021; 11(7): 672.
110.
GouldenRRiiseTMyhrKM, et al. Does low socioeconomic status in early life protect against multiple sclerosis? A multinational, case–control study. Eur J Neurol2016; 23(1): 168–174.
111.
MattarozziKBaldinEZenesiniC, et al. Effect of organizational features on patient satisfaction with care in Italian multiple sclerosis centres. Eur J Neurol2017; 24(4): 631–637.
112.
ProiettiFLandiDPonzanoM, et al. COVID-19 vaccine hesitancy among Italian people with multiple sclerosis. Neurol Sci2023; 44(3): 803–808.
113.
LandiDPonzanoMNicolettiCG, et al. Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis. Mult Scler Relat Disord2020; 45: 102359.
114.
LandiDPonzanoMNicolettiCG, et al. Patient’s point of view on the use of telemedicine in multiple sclerosis: A web-based survey. Neurol Sci2022; 43(2): 1197–1205.
115.
PoddaJTacchinoAPonzioM, et al. Mobile health app (DIGICOG-MS) for self-assessment of cognitive impairment in people with multiple sclerosis: Instrument validation and usability study. JMIR Form Res2024; 8: e56074.
116.
MaidaEMocciaMPalladinoR, et al. ChatGPT vs. neurologists: A cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis. J Neurol2024; 271(7): 4057–4066.
117.
PonzioMPignattelliEVerriA, et al. Job retention by people with disabilities: A qualitative study of the perspectives of people with multiple sclerosis. Med Lav2024; 115(3): e2024018.
118.
RaggiAGiovannettiAMSchiavolinS, et al. Development and validation of the multiple sclerosis questionnaire for the evaluation of job difficulties (MSQ-Job). Acta Neurol Scand2015; 132(4): 226–234.
119.
FilippiMGrimaldiLConteA, et al. Intravenous or subcutaneous natalizumab in patients with relapsing–remitting multiple sclerosis: Investigation on efficiency and savings—The EASIER study. J Neurol2024; 271(1): 340–354.
120.
BattagliaMKobeltGPonzioM, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy. Mult Scler2017; 23(Suppl. 2): 104–116.
121.
MattarozziKCasiniFBaldinE, et al. Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure. Health Expect2016; 19(2): 437–447.
122.
MocciaMFontanaLPalladinoR, et al. Determinants of early working impairments in multiple sclerosis. Front Neurol2022; 13: 1062847.
123.
SchiavolinSGiovannettiAMLeonardiM, et al. Multiple Sclerosis Questionnaire for Job Difficulties (MSQ-Job): Definition of the cut-off score. Neurol Sci2016; 37(5): 777–780.
124.
Anon. ECTRIMS 2024–ePoster. Mult Scler2024; 30(Suppl. 3): 681–1137.
125.
IncertiCCArgentoOMagistraleG, et al. Can personality traits influence occupational stress in multiple sclerosis patients? A one-year longitudinal study. Appl Neuropsychol Adult2020; 27(4): 390–392.
126.
Concetta IncertiCMagistraleGArgentoO, et al. Occupational stress and personality traits in multiple sclerosis: A preliminary study. Mult Scler Relat Disord2015; 4(4): 315–319.
127.
CioncoloniDInnocentiIBartaliniS, et al. Individual factors enhance poor health-related quality of life outcome in multiple sclerosis patients. Significance of predictive determinants. J Neurol Sci2014; 345(1–2): 213–219.
128.
MallucciGMontiMCPonzioM, et al. Impact of multiple sclerosis comorbidities on quality of life and job activity. Mult Scler2024; 30(8): 1047–1055.
129.
IncertiCCArgentoOMagistraleG, et al. Adverse working events in patients with multiple sclerosis. Neurol Sci2017; 38(2): 349–352.
130.
GiacoppoSGaluppoMCalabròRS, et al. Heavy metals and neurodegenerative diseases: An observational study. Biol Trace Elem Res2014; 161(2): 151–160.
131.
MontiniFNozzolilloARancoitaPMV, et al. Modifiable risk factors of COVID-19 in patients with multiple sclerosis: A single-centre case–control study. J Neurol2023; 270(4): 1835–1842.
132.
ZanghìAD’AmicoELucaM, et al. Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience. Mult Scler Relat Disord2020; 46: 102561.
133.
MotoleseFRossiMAlbergoG, et al. The psychological impact of COVID-19 pandemic on people with multiple sclerosis. Front Neurol2020; 11: 580507.
134.
ManteroVBasilicoPBalgeraR, et al. Flu-like syndrome due to interferon-beta injections does not increase anxiety, depression, and lost working days in multiple sclerosis patients during the Sars-CoV-2 pandemic. Clin Neurol Neurosurg2023; 232: 107892.
135.
PonzioMMontiMCMallucciG, et al. The economic impact of comorbidity in multiple sclerosis. Neurol Sci2023; 44(3): 999–1008.
136.
GiovannettiAMPietrolongoEBorreaniC, et al. Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy. PLoS ONE2020; 15(2): e0228587.
137.
GiovannettiAMBorreaniCBianchiE, et al. Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study. PLoS ONE2018; 13(7): e0200532.
138.
PonzioMTacchinoAVaccaroC, et al. Unmet needs influence health-related quality of life in people with multiple sclerosis. Mult Scler Relat Disord2020; 38: 101877.
139.
MocciaMAffinitoGRongaB, et al. Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy). Mult Scler2022; 28(4): 597–607.
140.
GiovannettiAMSchiavolinSRaggiA, et al. Psychosocial difficulties of individuals with multiple sclerosis: The PARADISE-24 questionnaire. Int J Rehabil Res2016; 39(4): 339–345.
141.
CorrealeLMartinisLTavazziE, et al. Barriers to exercise and the role of general practitioner: A cross-sectional survey among people with multiple sclerosis. Front Neurol2022; 13: 1016143.
142.
DonisiVPoliSMazziMA, et al. Promoting participatory research in chronicity: The ESPRIMO biopsychosocial intervention for young adults with multiple sclerosis. Front Psychol2022; 13: 1042234.
143.
CinoneNSantoroLSpinaS, et al. Reasons and determinants of BoNT-A treatment discontinuation in patients living with spasticity: A 10-year retrospective analysis. Toxins2022; 14(10): 675.
144.
ColaisPCasciniSBalducciM, et al. Impact of the COVID-19 pandemic on access to healthcare services amongst patients with multiple sclerosis in the Lazio region, Italy. Eur J Neurol2021; 28(10): 3403–3410.
145.
PuthenparampilMStivanelloCBanoMC, et al. Telehealth feasibility, interest, and satisfaction of patients with multiple sclerosis living in the Veneto Region, Italy, during the COVID-19 pandemic. Telemed J E Health2024; 30(11): 2676–2681.
146.
AltieriMCapuanoRBiseccoA, et al. Quality of care provided by Multiple Sclerosis Centers during COVID-19 pandemic: Results of an Italian multicenter patient-centered survey. Mult Scler Relat Disord2023; 77: 104870.
147.
FelicettiFTommasinSPetraccaM, et al. Eating hubs in multiple sclerosis: Exploring the relationship between Mediterranean diet and disability status in Italy. Front Nutr2022; 9: 882426.
148.
EspositoSSparacoMManiscalcoGT, et al. Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with multiple sclerosis. Mult Scler Relat Disord2021; 47: 102636.
149.
SolaroCCuccaroAGamberiniG, et al. Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy. Neurol Sci2020; 41(5): 1075–1079.
150.
BronziniMMaglioneARossoR, et al. Lower multiple sclerosis severity score is associated with higher adherence to Mediterranean diet in subjects with multiple sclerosis from Northwestern Italy. Nutrients2024; 16(6): 880.
151.
GuglielmettiMAl-QahtaniWHFerrarisC, et al. Adherence to Mediterranean diet is associated with multiple sclerosis severity. Nutrients2023; 15(18): 4009.
152.
Anon. ECTRIMS 2024–late breaking ePoster. Mult Scler2024; 30(Suppl. 3): 1212–1255.
153.
MerlinoGGarboRDal BelloS, et al. Ketogenic diet may improve sleep quality and daytime somnolence in patients affected by multiple sclerosis. Results of an exploratory study. Sleep Med2023; 112: 181–187.
154.
CavallaPGolzioPMaiettaD, et al. Dietary habits, nutritional status and risk of a first demyelinating event: An incident case-control study in a Southern European cohort. Neurol Sci2022; 43(7): 4373–4380.
155.
GuglielmettiMGrossoGFerrarisC, et al. Ultra-processed foods consumption is associated with multiple sclerosis severity. Front Neurol2023; 14: 1086720.
156.
SaresellaMMendozziLRossiV, et al. Immunological and clinical effect of diet modulation of the gut microbiome in Multiple Sclerosis patients: A pilot study. Front Immunol2017; 8: 1391.
157.
IvashynkaACopettiMNaldiP, et al. The impact of lifetime alcohol and cigarette smoking loads on multiple sclerosis severity. Front Neurol2019; 10: 866.
158.
IvashynkaALeoneMABarizzoneN, et al. The impact of lifetime coffee and tea loads on multiple sclerosis severity. Clin Nutr ESPEN2022; 47: 199–205.
159.
MieleGAbbadessaGCavallaP, et al. Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in multiple sclerosis patients treated with ocrelizumab: An Italian multi-center study. Mult Scler Relat Disord2022; 68: 104395.
160.
FerorelliPAntonelliFShevchenkoA, et al. Reduction in fatigue symptoms following the administration of nutritional supplements in patients with multiple sclerosis. Med Sci2021; 9(3): 52.
161.
NicolettiCGMonteleoneFMarfiaGA, et al. Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis. Mult Scler2020; 26(3): 304–311.
162.
PetraccaMQuarantelliMMocciaM, et al. ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial. Mult Scler Relat Disord2021; 56: 103274.
163.
PapettiLPanellaEMonteG, et al. Pediatric onset multiple sclerosis and obesity: Defining the silhouette of disease features in overweight patients. Nutrients2023; 15(23): 4880.
164.
Stampanoni BassiMIezziEButtariF, et al. Obesity worsens central inflammation and disability in multiple sclerosis. Mult Scler2020; 26(10): 1237–1246.
165.
LoreficeLDestroFFenuG, et al. The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis. Mult Scler Relat Disord2020; 39: 101886.
166.
WesnesKRiiseTCasettaI, et al. Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study. Mult Scler2015; 21(4): 388–395.
167.
ScartezziniATateoFPeriniP, et al. Association of multiple sclerosis with PM 2.5 levels. Further evidence from the highly polluted area of Padua Province, Italy. Mult Scler Relat Disord2021; 48: 102677.
168.
BergamaschiRMontiMCTrivelliL, et al. PM2.5 exposure as a risk factor for multiple sclerosis. An ecological study with a Bayesian mapping approach. Environ Sci Pollut Res2021; 28(3): 2804–2809.
169.
TateoFGrassivaroFErmaniM, et al. PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy. Mult Scler2019; 25(13): 1719–1727.
170.
VazifehdanMBosoniPTavazziE, et al. Continuous Markov models for analyzing the effect of environmental personal exposure on multiple sclerosis progression. In: GiacominiMBlobelBVeltriP (eds) Studies in health technology and informatics. Amsterdam: IOS Press, 2024, pp. 113–117.
171.
AngeliciLPiolaMCavalleriT, et al. Effects of particulate matter exposure on multiple sclerosis hospital admission in Lombardy region, Italy. Environ Res2016; 145: 68–73.
172.
BergamaschiRCorteseAPichiecchioA, et al. Air pollution is associated to the multiple sclerosis inflammatory activity as measured by brain MRI. Mult Scler2018; 24(12): 1578–1584.
173.
CorteseALovaLComoliP, et al. Air pollution as a contributor to the inflammatory activity of multiple sclerosis. J Neuroinflammation2020; 17(1): 334.
174.
BergamaschiRPonzanoMSchiavettiI, et al. The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. Eur J Neurol2022; 29(2): 535–542.
175.
PonzanoMSchiavettiIBergamaschiR, et al. The impact of PM2.5, PM10 and NO2 on COVID-19 severity in a sample of patients with multiple sclerosis: A case-control study. Mult Scler Relat Disord2022; 68: 104243.
176.
GiovannettiAMBrambillaLTorri ClericiV, et al. Difficulties in adjustment to multiple sclerosis: Vulnerability and unpredictability of illness in the foreground. Disabil Rehabil2017; 39(9): 897–903.
177.
LoreficeLFenuGFrauJ, et al. The burden of multiple sclerosis and patients’ coping strategies. BMJ Support Palliat Care2018; 8(1): 38–40.
178.
Delle FaveABassiMAllegriB, et al. Beyond disease: Happiness, goals, and meanings among persons with multiple sclerosis and their caregivers. Front Psychol2017; 8: 2216.
179.
ColaceciSZambriFMarchettiF, et al. “A sleeping volcano that could erupt sooner or later.” Lived experiences of women with multiple sclerosis during childbearing age and motherhood: A phenomenological qualitative study. Mult Scler Relat Disord2021; 51: 102938.
180.
SantangeloGCorteMDSparacoM, et al. Coping strategies in relapsing–remitting multiple sclerosis non-depressed patients and their associations with disease activity. Acta Neurol Belg2021; 121(2): 465–471.
181.
BassiMGrobberioMNegriL, et al. The contribution of illness beliefs, coping strategies, and social support to perceived physical health and fatigue in multiple sclerosis. J Clin Psychol Med Settings2021; 28(1): 149–160.
182.
PoddaJUccelliMMTacchinoA, et al. Predictors of mood disorders in parents with multiple sclerosis: The role of disability level, coping techniques, and perceived social support. Int J MS Care2022; 24(5): 224–229.
183.
Messmer UccelliMPonzioMTraversaS. What factors influence feeling competent as a parent with multiple sclerosis. Chronic Illn2022; 18(1): 46–57.
184.
Messmer UccelliMPonzioM. A case-control study assessing parenting sense of competence in people with multiple sclerosis. Rehabil Psychol2018; 63(3): 431–437.
185.
GiovannettiAMSolariAPakenhamKI, et al. Effectiveness of a group resilience intervention for people with multiple sclerosis delivered via frontline services. Disabil Rehabil2022; 44(22): 6582–6592.
186.
LavorgnaLRussoADe StefanoM, et al. Health-related coping and social interaction in people with multiple sclerosis supported by a social network: Pilot study with a new methodological approach. Interact J Med Res2017; 6(2): e10.
187.
GiovannettiAMBarabaschAGiordanoA, et al. Construction of a user-led resource for people transitioning to secondary progressive multiple sclerosis: Results of an international nominal group study. Front Neurol2020; 11: 798.
188.
DonisiVGajofattoAMazziMA, et al. Insights for fostering resilience in young adults with multiple sclerosis in the aftermath of the COVID-19 emergency: An Italian survey. Front. Psychiatry2021; 11: 588275.
189.
BonavitaSSparacoMRussoA, et al. Perceived stress and social support in a large population of people with multiple sclerosis recruited online through the COVID-19 pandemic. Eur J Neurol2021; 28(10): 3396–3402.
190.
CostabileTCarotenutoALavorgnaL, et al. COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management. Eur J Neurol2021; 28(10): 3375–3383.
191.
VolpeSGAhmadJPatelRA, et al. Author correction: Neurological care for LGBT+ people. Nat Rev Neurol2024; 20(10): 637–637.
192.
Florio-SmithJAyerMColhounS, et al. The importance of the patient’s perspective in decision-making in multiple sclerosis: Results of the OwnMS patient perspectives study. Mult Scler Relat Disord2023; 75: 104757.
193.
AmezcuaLRiveraVMVazquezTC, et al. Health disparities, inequities, and social determinants of health in multiple sclerosis and related disorders in the US: A review. JAMA Neurol2021; 78(12): 1515.
194.
DonkinAGoldblattPAllenJ, et al. Global action on the social determinants of health. BMJ Glob Health2018; 3(Suppl. 1): e000603.
195.
CylusJPapanicolasI. An analysis of perceived access to health care in Europe: How universal is universal coverage?Health Policy2015; 119(9): 1133–1144.
196.
MakSThomasA. Steps for conducting a scoping review. J Grad Med Educ2022; 14(5): 565–567.
197.
SemyonovLIarocciGBocciaA, et al. Socioeconomic differences in tobacco smoking in Italy: Is there an interaction between variables. Scientific World Journal2012; 2012: 286472–286477.
198.
WingerchukDM. Smoking: Effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord2012; 5(1): 13–22.
199.
RosoffDBClarkeTKAdamsMJ, et al. Educational attainment impacts drinking behaviors and risk for alcohol dependence: Results from a two-sample Mendelian randomization study with ~780,000 participants. Mol Psychiatry2021; 26(4): 1119–1132.
200.
CollinsSE. Associations between socioeconomic factors and alcohol outcomes. Alcohol Res2016; 38(1): 83–94.
201.
JacksonJWVanderWeeleTJ. Decomposition analysis to identify intervention targets for reducing disparities. Epidemiology2018; 29(6): 825–835.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
